Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion

Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) wi

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton

William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) wi

William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and

RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and

Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the ana

Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion t

Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lo

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company

Wells Fargo analyst Larry Biegelsen upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Equal-Weight

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and

B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutra

Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM,

Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a B

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and l

Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion t

Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the ana

FDA flags Class I recall for Tandem Mobi insulin pumps tied to software glitch that may halt insulin

TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and rais

Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and

MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising c

Analyst ratings changed for top Wall Street names. Morgan Stanley cut Carnival Corp price target, R

Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analy

Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold

Piper Sandler upgrades Tandem Diabetes, citing pharmacy shift, international growth, and Mobi launch

Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,

Top Wall Street analysts changed their outlook on top names. Upgrades include LMND, CSIQ, TNDM, ICHR

Piper Sandler analyst Matt O'Brien upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral t

Morgan Stanley analyst Patrick Wood maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Wei

Lake Street analyst Frank Takkinen upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy a

Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a H

U.S. stocks rise after Supreme Court decision on tariffs. Fear & Greed index eases but remains i

Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and ra

UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and rai

Stifel analyst Jonathan Block maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises

B of A Securities analyst Travis Steed upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Underperf

Piper Sandler analyst Matt O'Brien maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutra